Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response.

ABSTRACT: There has been little progress in the use of patient-derived xenografts (PDX) to guide individual therapeutic strategies. In part, this can be attributed to the operational challenges of effecting successful engraftment and testing multiple candidate drugs in a clinically workable timeframe. It also remains unclear whether the ancestral tumor will evolve along similar evolutionary trajectories in its human and rodent hosts in response to similar selective pressures (i.e., drugs). Herein, we combine a metastatic clear cell adenocarcinoma PDX with a timely 3 mouse x 1 drug experimental design, followed by a co-clinical trial to longitudinally guide a patient's care. Using this approach, we accurately predict response to first- and second-line therapies in so far as tumor response in m

SUBMITTER: Vargas R 

PROVIDER: S-EPMC6041303 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature